Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Invokana (canagliflozin) and Onglyza (saxagliptin) are both medications used to manage Type 2 diabetes, but they work in different ways and belong to different drug classes. Invokana is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps lower blood sugar by preventing the kidneys from reabsorbing sugar, which is then excreted through urine. Onglyza, on the other hand, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by blocking a protein that breaks down hormones responsible for insulin production, allowing insulin to stay in the body longer. Invokana is only available as a brand-name medication, while Onglyza is available in a lower-cost generic form. Invokana is taken once daily before the first meal, whereas Onglyza can be taken at any time of day, with or without food and once daily. Invokana has additional benefits like reducing the risk of heart and kidney problems, but it also carries risks such as genital infections and potential amputations. Onglyza has a lower risk of causing low blood sugar and weight gain but may increase the risk of heart failure in some individuals.
Invokana (canagliflozin)
Saxagliptin (Onglyza)
Invokana (canagliflozin)
Saxagliptin (Onglyza)
Summary of Invokana vs. Onglyza
Summary for SGLT2 inhibitor
Prescription only
Invokana (canagliflozin) is a medication that's used together with a healthy diet and exercise to lower blood sugar levels in adults with Type 2 diabetes. It can also lessen the chance of worsening heart and kidney problems in some people with Type 2 diabetes. This medication is taken by mouth once a day.
Summary for DPP-4 inhibitor
Prescription only
Saxagliptin (Onglyza) is an add-on medication to exercise and a balanced, nutritious diet to improve blood sugar control in adults with Type 2 diabetes. It belongs to the drug class called dipeptidyl peptidase-4 (DPP-4) inhibitors. The saxagliptin (Onglyza) dosage is taken by mouth once daily. Possible side effects include certain infections and headaches. The brand name, Onglyza, is no longer available. But the lower-cost generic version is still available.
Indications of Invokana vs. Onglyza
Indications for
•Type 2 diabetes
•Lowering the risk of major heart events (e.g., heart attack, stroke) in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization for heart failure, death due to heart problems, and worsening of kidney problems in certain adults with Type 2 diabetes and diabetic kidney disease